Singapore Clinical Trial: A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Study to Evaluate the Gastric Emptying Delay, Pharmacokinetics, Safety, and Tolerability of Eloralintide in Participants with Obesity or Overweight

Singapore, June 29 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Study to Evaluate the Gastric Emptying Delay, Pharmacokinetics, Safety, and Tolerability of Eloralintide in Participants with Obesity or Overweight'. The following are the other relevant details related to the trial:

Therapeutic Area: Clinical Pharmacology

Trial Centre(s): Lilly Centre for Pharmacology

Trial Status: NA

Principal Investigator(s): Dr Greg Li

Published by HT Digital Content Services with permission from Health Daily Digest....